Mucin synthesis inhibitors
AssigneeGenaera Corporation
InventorsYuhong Zhou, Roy C. Levitt, Nicholas C. Nicolaides, Steve Jones, Mike McLane
Life of this patent
Estimating the term…
Abstract
The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.
Claims41
A method of treating a subject with a disease characterized by the production of mucin, comprising administering to the subject an effective amount of a composition comprising at least one compound that decreases mucin synthesis or levels in the subject.
A therapeutic composition formulated for inhalation delivery to the lungs, comprising an amount effective to decrease mucin production or levels of at least one compound selected from the group consisting of talniflumate, flufenamic acid, niflumic acid, mefenamic acid, N-(3-fluorobenzyl)-3-aminoquinoline, salts thereof, derivates thereof and prodrugs thereof.
A method of 4, wherein the compound is administered orally.
A method of treating a subject with a disease characterized by the production of mucin, comprising administering to the subject an effective amount of a composition comprising at least one compound that decreases mucin synthesis or levels in the subject and inhibits a cyclooxygenase enzyme.
Dependencies are inferred from the claim text.